Parecoxib
{{drugbox |
| IUPAC_name = N-{[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]
sulfonyl}propanamide
| image = Parecoxib.svg
| CAS_number = 202409-33-4
| ATC_prefix = M01
| ATC_suffix = AH04
| PubChem = 119828
| DrugBank =
| C = 19 | H = 18 | N = 2 | O = 4 | S = 1
| molecular_weight = 370.422 g/mol
| bioavailability = 100%
| protein_bound = 98%
| metabolism = Hepatic to valdecoxib and propionic acid
CYP extensively involved (mainly CYP3A4 and 2C9)
| elimination_half-life = 22 minutes (parecoxib)
8 hours (valdecoxib)
| excretion = Renal (70%, metabolites)
| licence_EU = Dynastat
| pregnancy_category = Not recommended
| legal_UK = POM
| routes_of_administration = Intravenous and intramuscular
}}
Parecoxib is a water soluble and injectable prodrug of valdecoxib. It is marketed as Dynastat in the European Union.